Latest News - Gilead Sciences
Top Corporates Hub
Gilead Sciences
Nurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg Expansions
09.06.2026 09:59
Nurix (NRIX) stays a Strong Buy as bexobrutideg posts 83% ORR in r/r CLL and lands a $2.3B Roche dealâreview the catalysts, risks, and outlook now.
Gilead Sciences (GILD), Lakefront Biotherapeutics Acquire Ouro Medicines to Advance Autoimmune Pipeline
07.06.2026 04:39
Gilead Sciences Inc. (NASDAQ:GILD) is one of the best quality growth stocks to buy. On June 4, Gilead Sciences and Lakefront Biotherapeutics completed the acquisition of Ouro Medicines, a strategic move designed to bolster their inflammation and immunology pipelines. The centerpiece of this acquisition is gamgertamig (OM336), a clinical-stage T cell engager being developed as […]
How Investors Are Reacting To Gilead Sciences (GILD) Expanding Liver And Oncology Drug Footprint
03.06.2026 00:16
In late May 2026, Gilead Sciences reported new Phase 3 post hoc data showing that Livdelzi produced high, durable reductions in key liver markers for people with primary biliary cholangitis, while also securing accelerated U.S. approval for Hepcludex in chronic hepatitis delta and a positive EU opinion to broaden Trodelvy’s use in metastatic triple-negative breast cancer. These advances highlight how Gilead is consolidating its position in liver disease and oncology by deepening evidence for...
Gilead Sciences (GILD) Announces New Results From a Post Hoc Analysis
02.06.2026 14:14
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best inexpensive stocks to invest in right now. Gilead Sciences, Inc. (NASDAQ:GILD) announced on May 27 new results from a post hoc analysis that showed that Livdelzi® was associated with high and sustained rates of normalization of a key liver marker in people living with primary biliary […]
Gilead Sciences, Inc. (GILD) Gains Attention as Livdelzi Demonstrates Long-Term Efficacy and Safety
02.06.2026 14:11
We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most undervalued stocks to invest in. TheFly reported on May 27 that GILD presented long-term interim findings from the ongoing Phase 3 ASSURE study of Livdelzi at the 2026 European Association for the Study […]
Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
02.06.2026 12:30
FOSTER CITY, Calif., June 02, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from a Phase 3 study in people with primary biliary cholangitis (PBC), showing that treatment with Livdelzi® (seladelpar) led to significantly more patients achieving normalization of alkaline phosphatase (ALP), a key liver marker of disease progression, compared with placebo after 52 weeks. The primary endpoint was defined as a composite of ALP ≤ 1.0× upper limit of normal (ULN) and a ≥ 15%
"Starting Home Fires" HIV awareness campaign launches during National Indigenous History Month to promote HIV awareness
02.06.2026 12:00
As communities across Canada recognize National Indigenous History Month and prepare to mark National Indigenous Peoples Day on June 21, Indigenous leaders and HIV advocates are launching Starting Home Fires, a new Indigenous-led HIV awareness campaign designed to reduce stigma, increase knowledge, and support community-driven conversations about HIV.
Cencora to Support U.S. Distribution of Kite’s CAR T-Cell Therapies
02.06.2026 12:00
CONSHOHOCKEN, Pa., June 02, 2026--Cencora today announced an agreement with Kite, a Gilead Company, to support the distribution of Kite’s U.S. Food and Drug Administration (FDA)-approved CAR T-cell therapies, Yescarta® (axicabtagene ciloleucel) and Tecartus® (brexucabtagene autoleucel).
How Is Gilead Sciences's Stock Performance Compared to Other Healthcare Stocks
02.06.2026 09:53
Gilead Sciences has outperformed other healthcare stocks, and analysts remain highly optimistic about the stock’s outlook
Cencora To Support U.S. Distribution Of Gilead Subsidiary Kite's CAR T-Cell Therapies
02.06.2026 09:00
CONSHOHOCKEN, Pa. [June 2, 2026] — Cencora today announced an agreement with Kite , a Gilead Company (NASDAQ:GILD), to support the distribution of Kite's U.S. Food and Drug Administration (FDA)-approved CAR T-cell
Gilead Sciences Announces Results Of Phase 3 Study In People With Primary Biliary Cholangitis That Indicated Treatment With Livdelzi Led To Significantly More Patients Achieving Normalization Of Alkaline Phosphatase
02.06.2026 08:41
Gilead Sciences, Inc. (NASDAQ:GILD) today announced positive results from a Phase 3 study in people with primary biliary cholangitis (PBC), showing that treatment with Livdelzi® (seladelpar) led to significantly
Gilead: 'Hold' On Biktarvy Sales Growth And MM Drug Development Program
31.05.2026 09:46
Gilead (GILD) is rated Hold as BIKTARVY HIV growth offsets VEKLURY drag. Read the full analysis here.
Gilead (GILD) Wins FDA Approval for First HDV Treatment Hepcludex
29.05.2026 06:04
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable Stocks to Invest In. On May 22, 2026, the U.S. Food and Drug Administration approved Hepcludex injection, granted to Gilead Sciences, Inc. (NASDAQ:GILD), to treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis. The FDA said bulevirtide is the […]
Novel Spanish, Culturally Adapted Metastatic Breast Cancer Symptom Management Guide Debuts at ASCO 2026
28.05.2026 11:05
Viver Health is proud to announce a culturally adapted U.S. Spanish version of Your Guide to Managing Symptoms from Metastatic Breast Cancer Treatment (Spanish MBC Guide) available to U.S. healthcare professionals (HCPs) and debuting at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO).
FDA accelerated approval of Hepcludex significant milestone for US HDV market
28.05.2026 10:47
Hepcludex is now the first and only approved treatment for HDV patients in the US, marking a significant milestone for HDV patients and the HDV market.
3 Stocks Estimated To Be Trading At Discounts Of Up To 44.1%
26.05.2026 11:38
The United States market has shown robust performance, climbing 1.2% in the last week and rising 29% over the past year, with earnings projected to grow by 17% annually in the coming years. In such a thriving environment, identifying stocks that are trading below their intrinsic value can present attractive opportunities for investors seeking potential long-term gains.
Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference
24.05.2026 13:03
Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC Capital Markets senior biotech analyst Brian Abrahams. Berger said Gilead is focused on advancing Trodel
Is It Time To Reassess Gilead Sciences (GILD) After Strong Multi Year Share Price Gains
23.05.2026 07:18
If you are wondering whether Gilead Sciences at US$134.36 is still offering value, the starting point is to understand what the current market price is implying about the business. The stock has returned 3.7% over the last 7 days, 1.1% over the last 30 days, 10.5% year to date, 28.5% over 1 year, 92.9% over 3 years and 144.9% over 5 years, which gives useful context for how expectations and perceived risk have shifted over time. Recent coverage has focused on Gilead Sciences as a large...
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
22.05.2026 11:47
FOSTER CITY, Calif., May 22, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy® (sacituzumab govitecan-hziy) as a monotherapy for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metasta
Gilead Sciences completes Tubulis acquisition for $5bn
22.05.2026 11:19
Gilead acquired all outstanding equity of Tubulis for $3.15bn upfront, plus up to $1.85bn in milestone payments.